Chinese Journal of Pharmacovigilance ›› 2021, Vol. 18 ›› Issue (11): 1034-1038.
DOI: 10.19803/j.1672-8629.2021.11.08
Previous Articles Next Articles
ZHANG Xiaowen, HOU Wenbin, YANG Ming, LIU Jianping*
Received:
2020-07-15
Published:
2021-11-18
CLC Number:
ZHANG Xiaowen, HOU Wenbin, YANG Ming, LIU Jianping. Opportunities and Challenges of Pharmacovigilance in Cancer Treatment[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1034-1038.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2021.11.08
[1] WHO. Pharmacovigilance[EB/OL].(2020-01-20)[2021-06-10]. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/. [2] Yuan L, Gao Y, Lu CF.Priliminary thinking on the establishment of pharmacovigilance system in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2020, 17(11): 749-752. [3] International Council for Harmonisation. Medical Dictionary for Regulatory Activities [EB/OL].(2021-03-24)[2021-06-10]. https://www.meddra.org/. [4] National Cancer Institution. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0[R/OL].(2017-11-27)[2021-06-10]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. [5] National Cancer Institution. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE™)[R/OL].(2021-04-12)[2021-06-10].https://healthcaredelivery.cancer.gov/pro-ctcae/. [6] Crestan D, Trojniak MP, Francescon S, et al.Pharmacovigilance of anti-cancer medicines:opportunities and challenges[J]. Expert Opin DrugSaf, 2020, 19(7): 849-860. [7] Liu PC, Wang JY, Chen JM, et al.Pharmacovigilance Laws in Europe and America and their implications for China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(12): 877-882. [8] National Medical Products Administration. Announcement on the Direct Report of Adverse Reactions by the Holder of the Drug Marketing Authorization[EB/OL]. (2018-10-10)[2021-05-09].http://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_zdyz/201810/t20181010_40432.html. [9] Curigliano G, Cardinale D, Suter T, et al.Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2012, 23(Suppl 7): i155-i166. [10] Singh M, Alavi A, Wong R, et al.Radiodermatitis: a review of our current understanding[J]. Am J Clin Dermatol, 2016, 17(3): 277-292. [11] Van den Berg MH, Van Dijk M, Byrne J, et al. Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE)[J].Hum Reprod, 2021, 36(6): 1561-1573. [12] Shah RR, Curigliano G.Safety of novel targeted therapies in oncology[J]. Drug Saf, 2019, 42(2): 157-158. [13] Baraibar I, Melero I, Ponz-Sarvise M, et al.Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer[J]. Drug Saf, 2019, 42(2): 281-294. [14] Liebling DB, Cordova E, Deng G, et al.Pharmacovigilance of alternative medications in the cancer setting[J]. Cancer Treat Res, 2019, 171: 37-45. [15] National Medical Products Administration. The "weapon" of human beings against cancer-anticancer drugs [EB/OL].(2019-12-13)[2021-05-12]. https://www.nmpa.gov.cn/xxgk/kpzhsh/kpzhshyp/20191213163101824.html. [16] Shi YK, Sun Y.Manual of Medical Oncology(临床肿瘤内科手册)[M]. Beijing: People's Medical Publishing House, 2017: 42-45. [17] Shah RR.Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology[J]. Drug Saf, 2019, 42(2): 235-245. [18] Tewari D, Rawat P, Singh PK.Adverse drug reactions of anticancer drugs derived from natural sources[J]. Food Chem Toxicol, 2019, 123: 522-535. [19] Baldo P, Fornasier G, Ciolfi L, et al.Pharmacovigilance in oncology[J]. Int J Clin Pharm, 2018, 40(4): 832-841. [20] Wolf B, Zimmermann S, Arber C, et al.Safety and tolerability of adoptive cell therapy in cancer[J]. Drug Saf, 2019, 42(2): 315-334. [21] Smith BD, Smith GL, Hurria A, et al.Future of cancer incidence in the United States: burdens upon an aging, changing nation[J]. J Clin Oncol, 2009, 27(17): 2758-2765. [22] Murugappan MN, King-Kallimanis BL, Reaman GH, et al. Patient reported outcomes in pediatric cancer registration trials: a u.s. food and drug administration perspective[J]. J Natl Cancer Inst, 2021(1): djab087. [23] Shachar SS, Gallagher K, Mcguire K, et al.Multidisciplinary management of breast cancer during pregnancy[J]. Oncologist, 2017, 22(3): 324-334. [24] Cardonick E, Iacobucci A.Use of chemotherapy during human pregnancy[J]. Lancet Oncol, 2004, 5(5): 283-291. [25] Létinier L, Jouganous J, Benkebil M, et al.Artificial Intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions[J]. Clin Pharmacol Ther, 2021, 110(2): 392-400. [26] Lavertu A, Vora B, Giacomini KM,et al.A new era in pharma-covigilance: toward real-world data and digital monitoring[J]. Clin Pharmacol Ther, 2021, 109(5): 1197-1202. [27] Khosla S, White R, Medina J, et al.Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?[J]. F1000Research, 2018, 7: 111. [28] Harb H, Mroue H, Mansour A, et al.A hadoop-based platform for patient classification and disease diagnosis in healthcare applications[J]. Sensors (Basel) , 2020, 20(7): 1931. [29] Beninger P, Murray M.Review of FDA amendments act section 921 experience in posting data-mining results from the FAERS Database[J]. Clin Ther, 2021, 43(2): 380-395. [30] Perino J, Mottal N, Bohbot Y, et al.Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports and disproportionality analyses in Vigibase[J]. Br J Clin Pharmacol, 2020, 86(5): 991-998. [31] Patras DCE, Bondon-Guitton E, Laurent G, et al.Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacod-ynamics[J]. Br J Clin Pharmacol, 2017, 83(7): 1544-1555. [32] Li R, Curtain C, Bereznicki L, et al.Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey[J]. Int J Clin Pharm, 2018, 40(4): 878-889. [33] Inácio P, Cavaco A, Airaksinen M.The value of patient reporting to the pharmacovigilance system: a systematic review[J]. Br J Clin Pharmacol, 2017, 83(2): 227-246. [34] Ni X.Construction and evaluation of self-management support module based on mobile-health for lung cancer patients[D]. Hangzhou Normal University, 2019. [35] Rolfes L, van Hunsel F, Wilkes S, et al. Adverse drug reaction reports of patients and healthcare professionals-differences in reported information[J]. Pharmacoepidemiol Drug Saf, 2015, 24(2): 152-158. [36] Monestime S, Page R, Jordan WM, et al.Prevalence and predictors of patients reporting adverse drug reactions to health care providers during oral targeted cancer treatment[J]. J Am Pharm Assoc (2003), 2021, 61(1): 53-59. [37] Von Itzstein MS, Smith ML, Railey E, et al.Accessing targeted therapies: a potential roadblock to implementing precision Oncology?[J]. JCO Oncol Pract, 2021: P2000927. [38] Biagi C, Montanaro N, Buccellato E, et al.Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region)[J]. Eur J Clin Pharmacol, 2013, 69(2): 237-244. [39] Sessa M, di Mauro G, Mascolo A, et al. Pillars and Pitfalls of the new pharmacovigilance legislation: consequences for the identification of adverse drug reactions deriving from abuse, misuse, overdose, occupational exposure, and medication errors[J]. Front Pharmacol, 2018, 9: 611. [40] Chua IS, Gaziel-Yablowitz M, Korach ZT, et al.Artificial intelli-gence in oncology: Path to implementation[J].Cancer Med, 2021, 10(12): 4138-4149. [41] Drago JZ, Gönen M, Thanarajasingam G, et al.Inferences about drug safety in phase iii trials in oncology: examples from advanced prostate cancer[J]. J Natl Cancer Inst, 2021, 113(5): 553-561. [42] Fitzner K, Oteng-Mensah F, Donley P, et al.Safety of cancer therapies: at what cost?[J]. Popul Health Manag, 2017, 20(4): 318-328. [43] Formica D, Sultana J, Cutroneo PM, et al.The economic burden of preventable adverse drug reactions: a systematic review of observ-ational studies[J]. Expert Opin Drug Saf, 2018, 17(7): 681-695. [44] Fitzner K, Oteng MF.Impact of cost on the safety of cancer pharmaceuticals[J]. Cancer Treat Res, 2019, 171: 1-20. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[3] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[4] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[5] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[6] | CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215. |
[7] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[8] | GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19. |
[9] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[10] | JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106. |
[11] | CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110. |
[12] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[13] | LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||